Cargando…

The immune and metabolic treatment approach of using testosterone on mice models of liver injury

Background: Natural killer (NK) cells showed an anti-fibrotic effect; however, their function is thought to be impaired in advanced liver injury. In the current study, we aimed to assess the immune and metabolic impact of testosterone on mice models of liver injury. Methods: Carbon-tetrachloride ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Amer, Johnny, Salhab, Ahmad, Snobar, Hadeel, Alhabil, Yazan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442657/
https://www.ncbi.nlm.nih.gov/pubmed/37614321
http://dx.doi.org/10.3389/fphar.2023.1219709
_version_ 1785093653949054976
author Amer, Johnny
Salhab, Ahmad
Snobar, Hadeel
Alhabil, Yazan
author_facet Amer, Johnny
Salhab, Ahmad
Snobar, Hadeel
Alhabil, Yazan
author_sort Amer, Johnny
collection PubMed
description Background: Natural killer (NK) cells showed an anti-fibrotic effect; however, their function is thought to be impaired in advanced liver injury. In the current study, we aimed to assess the immune and metabolic impact of testosterone on mice models of liver injury. Methods: Carbon-tetrachloride induced liver fibrosis male mice models was i.p injected for 2 weeks (acute) and 4 weeks (chronic) (n = 36). Testosterone (4 mg/kg mouse body weight) was injected i.p. following the first week of the acute model of CCl(4) and following the second week of the chronic model of CCl(4). At the end of the experiments, mice were sacrificed, and serum was collected for assessing liver enzymes of ALT and AST, as well as inflammatory markers of IL-6, metabolic makers of C-peptide levels, and lipid and glucose profiles. Livers were harvested and used for histological assessments for inflammation and fibrosis. Fibrosis profiles from liver extracts, αSMA and Collagen III, were assessed by RT-PCR. Moreover, liver tissue-resident NK cells were isolated and evaluated for their activity by assessing INF-γ and IL-6 receptors using ELISA and flow cytometry, respectively. Results: Serum ALT, AST, and IL-6, as well as metabolic assessments of cholesterol, triglyceride, C-peptide, fasting blood sugar, and fibrotic profiles, were linearly correlated with disease progressions. Histological characterization of the liver was worsened in the chronic model of liver injury. Testosterone-treated mice exhibit a significant reduction in collagen depositions with less dense fibrosis tissue associated with reduced liver injury enzymes and metabolic markers in both the acute and chronic CCl(4) mice models in favor of the latter one (p < 0.05). Moreover, testosterone treatments displayed a significant decrease in serum IL-6 of 2.4-fold (p = 0.0001) and 2.3-fold (p = 0.0003) in the acute and chronic models, respectively (p = 0.002), and data showed an increase in INF-γ release from NK associated with a reduction in their IL-6 receptor expressions (p < 0.05). Conclusion: Our results indicated effects of testosterone on mediating a decreased expressions of NK IL-6 receptors and consequently inducing their activation; which in part, could explain the amelioration of liver injury. Our data suggest an anti-inflammatory and anti-fibrotic treatment approach of using testosterone for delaying disease progressions.
format Online
Article
Text
id pubmed-10442657
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104426572023-08-23 The immune and metabolic treatment approach of using testosterone on mice models of liver injury Amer, Johnny Salhab, Ahmad Snobar, Hadeel Alhabil, Yazan Front Pharmacol Pharmacology Background: Natural killer (NK) cells showed an anti-fibrotic effect; however, their function is thought to be impaired in advanced liver injury. In the current study, we aimed to assess the immune and metabolic impact of testosterone on mice models of liver injury. Methods: Carbon-tetrachloride induced liver fibrosis male mice models was i.p injected for 2 weeks (acute) and 4 weeks (chronic) (n = 36). Testosterone (4 mg/kg mouse body weight) was injected i.p. following the first week of the acute model of CCl(4) and following the second week of the chronic model of CCl(4). At the end of the experiments, mice were sacrificed, and serum was collected for assessing liver enzymes of ALT and AST, as well as inflammatory markers of IL-6, metabolic makers of C-peptide levels, and lipid and glucose profiles. Livers were harvested and used for histological assessments for inflammation and fibrosis. Fibrosis profiles from liver extracts, αSMA and Collagen III, were assessed by RT-PCR. Moreover, liver tissue-resident NK cells were isolated and evaluated for their activity by assessing INF-γ and IL-6 receptors using ELISA and flow cytometry, respectively. Results: Serum ALT, AST, and IL-6, as well as metabolic assessments of cholesterol, triglyceride, C-peptide, fasting blood sugar, and fibrotic profiles, were linearly correlated with disease progressions. Histological characterization of the liver was worsened in the chronic model of liver injury. Testosterone-treated mice exhibit a significant reduction in collagen depositions with less dense fibrosis tissue associated with reduced liver injury enzymes and metabolic markers in both the acute and chronic CCl(4) mice models in favor of the latter one (p < 0.05). Moreover, testosterone treatments displayed a significant decrease in serum IL-6 of 2.4-fold (p = 0.0001) and 2.3-fold (p = 0.0003) in the acute and chronic models, respectively (p = 0.002), and data showed an increase in INF-γ release from NK associated with a reduction in their IL-6 receptor expressions (p < 0.05). Conclusion: Our results indicated effects of testosterone on mediating a decreased expressions of NK IL-6 receptors and consequently inducing their activation; which in part, could explain the amelioration of liver injury. Our data suggest an anti-inflammatory and anti-fibrotic treatment approach of using testosterone for delaying disease progressions. Frontiers Media S.A. 2023-08-08 /pmc/articles/PMC10442657/ /pubmed/37614321 http://dx.doi.org/10.3389/fphar.2023.1219709 Text en Copyright © 2023 Amer, Salhab, Snobar and Alhabil. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Amer, Johnny
Salhab, Ahmad
Snobar, Hadeel
Alhabil, Yazan
The immune and metabolic treatment approach of using testosterone on mice models of liver injury
title The immune and metabolic treatment approach of using testosterone on mice models of liver injury
title_full The immune and metabolic treatment approach of using testosterone on mice models of liver injury
title_fullStr The immune and metabolic treatment approach of using testosterone on mice models of liver injury
title_full_unstemmed The immune and metabolic treatment approach of using testosterone on mice models of liver injury
title_short The immune and metabolic treatment approach of using testosterone on mice models of liver injury
title_sort immune and metabolic treatment approach of using testosterone on mice models of liver injury
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442657/
https://www.ncbi.nlm.nih.gov/pubmed/37614321
http://dx.doi.org/10.3389/fphar.2023.1219709
work_keys_str_mv AT amerjohnny theimmuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury
AT salhabahmad theimmuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury
AT snobarhadeel theimmuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury
AT alhabilyazan theimmuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury
AT amerjohnny immuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury
AT salhabahmad immuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury
AT snobarhadeel immuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury
AT alhabilyazan immuneandmetabolictreatmentapproachofusingtestosteroneonmicemodelsofliverinjury